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versity, SE.221 85 Lund, Sweden. E-mail: pia.sundgren@med.lu.se
Received January 29, 2010; Accepted October 5, 2010.
DOI 10.1002/jmri.22413
View this article online at wileyonlinelibrary.com.
This article is accredited as a journal-based CME acitivity.
If you wish to receive credit for this activity, please refer to
the website: www.wileyblackwellcme.com
ACCREDITATION AND DESIGNATION STATEMENT
Blackwell Futura Media Services designates this journal-
based CME activity for a maximum of 1 AMA PRA Category
1 CreditTM. Physicians should only claim credit commensu-
rate with the extent of their participation in the activity.
Blackwell Futura Media Services is accredited by the Ac-
creditation Council for Continuing Medical Education to
provide continuing medical education for physicians.
EDUCATIONAL OBJECTIVES
Upon completion of this educational activity, participants will
be better able to discuss the use of gadolinium-based contrast
media in pregnant or lactating women and small children.
ACTIVITY DISCLOSURES
No commercial support has been accepted related to the
development or publication of this activity.
Faculty Disclosures:
The following contributors have no conflicts of interest to
disclose:
Editor-in-Chief: C. Leon Partain, MD, PhD
CME Editor: Scott B. Reeder, MD, PhD
CME Committee: Scott Nagle, MD, PhD, Pratik Mukher-
jee, MD, PhD, Shreyas Vasanawala, MD, PhD, Bonnie Joe,
MD, PhD, Tim Leiner, MD, PhD, Sabine Weckbach, MD,
Frank Korosec, PhD
Authors: Pia C. Sundgren, MD, PhD, Peter Leander, PhD
This manuscript underwent peer review in line with
the standards of editorial integrity and publication ethics
maintained by Journal of Magnetic Resonance Imaging. The
peer reviewers have no relevant financial relationships. The
peer review process for Journal of Magnetic Resonance
Imaging is double-blinded. As such, the identities of the
reviewers are not disclosed in line with the standard
accepted practices of medical journal peer review.
Conflicts of interest have been identified and resolved
in accordance with Blackwell Futura Media Services’s Policy
on Activity Disclosure and Conflict of Interest. No relevant fi-
nancial relationships exist for any individual in control of the
content and therefore there were no conflicts to resolve.
INSTRUCTIONS ON RECEIVING CREDIT
For information on applicability and acceptance of CME
credit for this activity, please consult your professional
licensing board.
This activity is designed to be completed within an hour;
physicians should claim only those credits that reflect the
time actually spent in the activity. To successfully earn
credit, participants must complete the activity during the
valid credit period, which is up to two years from initial
publication.
Follow these steps to earn credit:
 Log on to www.wileyblackwellcme.com
 Read the target audience, educational objectives, and
activity disclosures.
 Read the article in print or online format.
 Reflect on the article.
 Access the CME Exam, and choose the best answer to
each question.
 Complete the required evaluation component of the
activity.
This activity will be available for CME credit for twelve
months following its publication date. At that time, it will
be reviewed and potentially updated and extended for an
additional twelve months.
JOURNAL OF MAGNETIC RESONANCE IMAGING 34:750–757 (2011)
CME
VC 2011 Wiley-Liss, Inc. 750
The use of gadolinium-based contrast media in preg-
nant or lactating women has been discouraged at many
radiology departments due to the lack of knowledge of the
risks for the fetus and the unwillingness to expose neo-
nates to unnecessary drugs. In the present review the
current literature and present guidelines regarding the
use of gadolinium-based contrast media have been
reviewed to validate the justification for their administra-
tion to pregnant or lactating women and small children.
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TODAY IT IS GENERALLY ACCEPTED that magnetic
resonance imaging (MRI) can be performed in preg-
nant women if considered necessary. According to the
American College of Radiology’s 2007 White Paper for
safe MR practices, MRI may be used in pregnant
women if considered necessary by referring physi-
cians and attending radiologists, irrespective of gesta-
tional age (1). The patient can be informed that, to
date, there are no known harmful effects from the use
of clinical MRI at 1.5 T or lower magnetic field
strengths (2). As there is lack of experience with the
use of field strengths greater than 2.5 T in pregnant
women, the use of higher field strength than 1.5 T
should be avoided in pregnant women at present (3).
In addition, when it is clinically indicated to perform
MR in a pregnant woman due to her illness (not for fe-
tal MR), it is recommended that written informed con-
sent be obtained to document the patients’ under-
standing of the risk–benefit ratio and if alternative
diagnostic options are available to answer the clinical
question at hand (1).
When examinations using MRI are considered during
pregnancy they are often performed without gadolin-
ium-enhanced images due to the concern for potential
harmful effects of the contrast medium to the fetus.
The decision to administer contrast media for MRI
in pregnant women is controversial. Despite the lack
of evidence of any harmful effects, the general rule
within the radiological community is to avoid injec-
tion of contrast media to pregnant women out of gen-
eral cautiousness. Asked for the primary reason not
giving gadolinium-based contrast media to pregnant
women in a recent small survey including 20 aca-
demic centers, the majority of centers reported the
risk to the fetus as the major reason for avoiding
contrast administration (4).
Gadolinium is classified as a category C drug by the
U.S. Food and Drug Administration (FDA) and can be
used if considered critical; in other words, it should
be administered only if the potential benefits justify
the potential risk to the fetus. Gadolinium is harmless
in chelated form but severely toxic in its free form.
Both animal and human studies have shown that
gadolinium crosses the placenta, and is extracted by
the fetal kidneys into the amniotic fluid (5–12). In this
location, gadolinium chelate molecules remain for a
relatively long period before finally being reabsorbed
and eliminated. The longer the chelate molecule
remains in this space, the greater the potential for dis-
sociation of gadolinium ion from its chelate molecule
(1). The recommendations in the recent 2007 American
College of Radiology Guidance Document for safe MRI
practices are that intravenous gadolinium should be
avoided during pregnancy and should only be used if
absolutely essential for the diagnosis (1).
There are barely any reports in the literature on the
value of the indiscriminate use of intravenous con-
trast media administration in MRI of small children. A
few recent studies, performed by one group, focused on
the brain and spine and demonstrated that indiscrimi-
nate use of intravenous contrast media to neonates and
infants (under the age of 2 years) neither helped in the
diagnosis nor in detecting abnormalities (13–15). In
other instances, such as certain studies of congenital
heart disease and evaluation of abdominal disease, eg,
neuro- and nephroblastoma contrast-enhanced exami-
nations may be necessary and are judged justified.
The purpose of this article is to review the literature
and existing guidelines to see if there is ever a justifi-
cation to give nonspecific extracellular gadolinium-
based contrast media to pregnant women and what
rules should apply if contrast is given to lactating
women or to small children.
ANIMAL STUDIES
Toxic Effects to Fetus
Some previous animal studies with all of the by-now
approved contrast media have shown potential fetal
toxic effects with growth retardation and congenital
anomalies. The effects have been observed when these
media were administered at doses two to seven times
higher than those used in humans and/or during
extensive periods of exposure (16–21).
Other preclinical studies have not shown any poten-
tial negative effects on the fetus (22–26). In a study of
700 mice fetuses, investigating the results of exposure
of pregnant mice to the combination of MRI and gado-
pentetate dimeglumine (Magnevist) at 9.5 days of ges-
tation, the authors found no evidence of an increase
in abortions, stillbirths, or grossly detectable eye, ear,
facial, limb, or extremity defects (23). In another study
by the same group no detectable chromosomal dam-
ages were demonstrated in 18 rats injected with 1.14–
1.6 mmol/kg of gadopentetate dimeglumine, a dose that
is more than 11–16 times the recommended clinical
dose (26). There have been no long-term animal studies
to evaluate the carcinogenic potential of gadolinium-
based contrast media. In animals exposed in utero to
clinical dosages of gadolinium-based contrast media, no
carcinogenic or mutagenic effects have been observed
and no other long-term effects have occurred (22–26).
Placental Transfer of Gadolinium-Based
Contrast Media
Gadolinium contrast media have been shown in the
placenta following intravenous contrast administra-
tion to the mother in animals. In eight pregnant
rabbits at third trimester the highest placental
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gadolinium concentration occurred 5 minutes after an
injection of 0.1 mmol/kg of gadopentetate dimeglu-
mine (Magnevist), with a 50% decrease present at
60 minutes (9). The placental concentrations of gado-
linium were initially high (16.6 6 3.4 mg/g) and then
declined with a biexponential pattern. Initial gadolin-
ium levels in the fetal organs were low and remained
so except for the fetal kidneys, which showed increased
levels of gadolinium from 4.3 6 1.1 mg/g at 5 minutes
to 6.8 6 1.8 mg/g at 60 minutes. Similar findings have
been seen in a study in pregnant rats (10). In that
study 0.3 mmol/kg 14C-labeled gadodiamide (Omnis-
can) were injected to the rats on day 18 of gestation,
with the highest placental concentration present at the
end of the injection, equal to between 18%–30% of the
injected dose. There was a decrease of about 100-fold
by 24 hours, with the majority of the decrease occur-
ring in the first 4 hours (10). Other animal models
including a study of 22 pregnant BALB/c mice injected
with double and quadruple the clinical dose have dem-
onstrated contrast-enhanced MRI to be effective in the
measurement of placental blood flow and rate of trans-
fer of contrast material between the maternal and fetal
circulation (11).
HUMAN STUDIES
Toxic Effect to Fetus
To date, no adequate, well-controlled studies in
humans regarding the potential effects of in utero ex-
posure to intravenous gadolinium-based contrast
media have been performed.
Placental Transfer of Gadolinium Contrast Media
In one of the few clinical studies of placental imaging
performed in 11 women between 16 and 37 weeks of
pregnancy, gadolinium uptake into the placenta follow-
ing a single dose of 0.1 mmol/kg body weight of gadopen-
tetate dimeglumine (Magnevist) was enough for imaging
of the placenta with no adverse effects noted (12).
It has been demonstrated that gadolinium-
enhanced dynamic MRI can provide excellent contrast
between the myometrium and placenta in a study of
six pregnant women with prior cesarean section,
examined at 34–38 gestational weeks (27).
Important, regarding placental imaging, as has been
pointed out before, is that the indication to image usu-
ally arises after the 36th week of gestation, just prior to
delivery, well beyond the period of organogenesis (28).
Effects on Neonates After Gadolinium
Administration in Pregnant Women
There are few clinical reports of the effects on neo-
nates after administration of gadolinium contrast
media to the mother in the first trimester.
No adverse effects were seen in the neonates after
intentional gadolinium administration in a limited
study of two pregnant women with Crohn’s disease
during the first trimester (29), or in one case of inad-
vertent gadolinium exposure during the first trimester
(30). In a more recent study of 26 pregnant women
exposed to gadolinium-based contrast media in the
first trimester, no adverse effects on pregnancy and
neonatal outcome were seen (31).
Reports on the use of gadolinium-based contrast
agents during the second or third trimester do exist
underscoring the usefulness of these agents in dia-
gnosing various conditions. No harm to the fetus and
neonates has been documented in these reports
(12,27,32,33). A recent study using gadolinium in preg-
nant women, evaluating placenta accreta, demonstrated
that contrast-enhanced MRI improves the diagnostic
accuracy compared to nonenhanced, T2-weighted imag-
ing (27). Three of the newborns in that study suffered
from perinatal complications of fetal distress or meco-
nium staining (27). Whether this was related to the MRI
study is unknown but must, in our opinion, be consid-
ered less likely, as these studies were performed imme-
diately prior to delivery and the exposure to the contrast
agent was limited.
In a present study of 29 pregnant women with a
mean gestational age of 27 weeks (ranging from 13–
31 weeks) with acute abdominal and pelvic pain,
seven received contrast agent (0.1 mmol/kg Omnis-
can) to aid in the diagnosis without any reported
adverse events to the fetus (33). Also in a study evalu-
ating the placenta in 11 pregnant women, no adverse
effects and no abnormalities to the child were
detected after birth (27). Symptomatic hydronephrosis
has been studied in 11 women at 19–34 weeks of ges-
tation, injected with 0.1 mmol/kg of gadopentetate
dimeglumine (Magnevist) with no reported adverse
effects to the neonates at delivery (34).
However, there are institutions that do not use gad-
olinium agents in pregnant women in their studies. In
a recent review of the use of MRI in pregnant and non-
pregnant women with acute right lower quadrant pain,
no contrast media was given to the pregnant women
(35). Contrast was neither given in another study eval-
uating the value of MRI in pregnant women with acute
abdominal and pelvic pain (36) nor in an MRI study of
acute appendicitis in pregnant women (37).
Current Practice
In a published survey from 183 radiology residency
programs in the U.S., evaluating current practice pat-
terns in the imaging of pregnant women with abdomi-
nal complaints 94% of the centers performed MRI in
pregnant women but only 33% gave intravenous gado-
linium agents (38). The most common indication for
the administration of gadolinium was malignancy
staging. The majority of the centers preferred MRI
over computed tomography (CT) for imaging of appen-
dicitis and abscesses in the first trimester (39% vs.
32% and 46% vs. 32%), while in the second and third
trimester most centers preferred CT (38). At the 2009
annual meeting of the ISMRM a small survey that
evaluated the current practice from 18 academic cen-
ters in Europe, Asia, and the USA presented similar
findings: 33% of them gave gadolinium to pregnant
women, 67% gave gadolinium in all three trimesters,
whereas 33% only in the third trimester (4).
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In summary, to our knowledge and supported by
the limited reports in the literature, there have been
no known adverse effects to human fetuses reported
to date when clinically recommended dosages of gado-
linium-based contrast media have been given to preg-
nant women. There are no studies supporting the use
of one gadolinium-based contrast medium before the
other to pregnant women. However, the Contrast
Media Safety Committee of the European Society of
Urogenital Radiology (39) recommends the use of the
most stable agents, ie, macrocyclic agents.
Risk of Gadolinium-Based Contrast Medium
Administration During Lactation
The recommendations regarding lactating women who
receive intravascular gadolinium have been inconsis-
tent over the course of time. Previously it was gener-
ally recommended to stop breastfeeding for 24 hours
after gadolinium administration. The earlier guide-
lines from the Contrast Media Safety Committee of the
European Society of Urogenital Radiology (v. 6.0) to-
gether with a published article (40) stated that breast-
feeding could be continued. However, in the most
recent version (7.0) it is stated that breastfeeding
should be avoided 24 hours after gadolinium has
been used (39). From a scientific point of view the ra-
tionale for lactating women to discontinue breastfeed-
ing for 24 hours and to discard all milk expressed
during this time is extremely weak. The recommended
pediatric dose of gadolinium agents is 0.1–0.2 mmol/
kg and this dose is considered well tolerated in
infants less than 6 months old (41–44). Several recent
studies have shown that only a tiny amount of gado-
linium-based contrast medium given to a lactating
woman reaches her milk (45–47). A study of 20 lactat-
ing women given 0.1 mmol/kg gadopentetate dimeglu-
mine (Magnevist) (19 of the 20 women) and
0.2 mmol/kg (1/20) showed that less than 0.04% of
the total maternal dose of intravenous gadolinium
passes into the breast milk, which means that the
amount transferred to a nursing infant orally would
be less than 1% of the permitted intravenous dose for
neonates (44). Similar results have been observed in
other studies of lactating women. In a lactating
woman who received 0.1 mmol/kg of gadopentetate
dimeglumine (Magnevist) the cumulative excreted
dose of gadolinium was 0.011% of the total dose given
(46) and in another study of a lactating woman given
the same dose of gadopentetate dimeglumine the cu-
mulative gadolinium excretion was 0.023% of the
administrated dose over 24 hours (47).
The small fraction of the agent should be evaluated
in conjunction with the small fraction taken up
through the infant gut. Hence, only a very minute sys-
temic dose to the infant will be the result after gado-
linium administration to the mother (44).
Based on these facts we believe there is no reason
to discontinue breastfeeding for 24 hours. This is in
accord with several other authors (45,48,49). The
change in the guidelines from the Contrast Media
Safety Committee of the European Society of Urogeni-
tal Radiology may reflect the attention paid to nephro-
genic systemic fibrosis (NSF) (see below).
Gadolinium-Based Contrast Media Administration
in Children
The commonly used gadolinium-based contrast media,
Magnevist, Ominscan, and MultiHance, have been pro-
ven safe also for children and are used in children
under the age of 6 months (41–44), in children 6
months and older (50), and in children >2 years (51).
The reported frequencies of adverse events in the
pediatric population from intravenously administrated
gadolinium-based contrast media are rare (52,53). In a
recent retrospective study of 13,344 pediatric patients
(younger than 19 years) the reported frequency of
adverse events was 0.04%, with the majority of the
events being mild and no deaths occurred (52).
The practice to give contrast to children varies in
different institutions depending on their routine. At
some institutions all pediatric examinations are
supervised by radiologists who decide in the course of
the examination about the administration of gadolin-
ium when appropriate, while other institutions use
predefined routine protocols which often include rou-
tine gadolinium administration. In a survey from 20
academic centers by Sundgren (4), the majority of the
centers (87%) reported supervising all pediatric
examinations. Images after contrast administration
were included in the routine imaging protocol at
almost half of the centers (47%), but of those 87%
reported that they decide at the time of the study if
contrast agent should be given or not (4).
Supervising pediatric MR examinations may hamper
effectiveness, as it may limit the examinations to reg-
ular work-hours. The major reasons to not supervise
the individual examinations are: the use of routine
protocols selected based on clinical information, the
performance of the examinations at off-hours, and time
efficiency (4). Overall, it does not seem that many insti-
tutions have changed their protocols for small children
despite concern of risk of NSF. In the survey, 20%
reported that they have changed their imaging proto-
cols for small children (4). The remaining have not
changed because they had already restricted protocols.
However, 7% reported that they feel that contrast is
administrated too often in children (4).
In a few recent publications by one group the indis-
criminate use of gadolinium in neuroimaging has
been discussed (13–15). The authors concluded that
1) there is no general need for gadolinium in MRI of
the brain in children younger than 2 years of age,
with clinical questions regarding seizures and devel-
opmental delay; and 2) that gadolinium-based con-
trast media administration should be reserved for
those with suspected or known brain infection and
malignancy (13,14). In one study of 437 MRI in chil-
dren younger than 2 years of age with the clinical
question of first-time seizures, the authors evaluated
if contrast administration was useful. The contrast
administration was rated as essential, helpful, or not
helpful for each study. The authors concluded that
administration of contrast medium was felt to be
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essential in formulating a diagnosis in a total of 8
(1.8%) studies, all of which involved documented or
highly suspected cases of infection. In an additional
26 cases (5.9%), which included four cases of neo-
plasm, contrast was felt to be useful but not essential
in reaching a diagnosis. Contrast was judged not
helpful in making the diagnosis in the other 403 of
the 437 studies (92.3%) (13). The same investigators
also reviewed the MRI of 107 children under the age
of 2 years in whom developmental delay was the pri-
mary or secondary concern (14). They concluded that
there were no cases in which the findings would have
been missed without gadolinium administration in the
children with developmental delay as the primary con-
cern. In the 63 patients in whom developmental delay
was a secondary concern, there were several cases
(11%) where contrast was helpful but not essential in
reaching a radiologic diagnosis. The authors con-
cluded that intravenous gadolinium has an extremely
low yield in children under the age of 2 when develop-
mental delay is the primary concern. In young chil-
dren in whom developmental delay is a secondary
concern, they advocated the use of gadolinium partic-
ularly when tumor or infection is clinically suspected
(14). Similar ideas have previously also been sug-
gested by others (54).
Similarly, the value of contrast administration was
considered to be limited in MRI of the spine in chil-
dren younger than 2 years of age (15). In a recent MRI
study of the spine in 186 children under the age of 2
years we evaluated the value of contrast administra-
tion in the spine. The contrast administration was
rated as essential, helpful, or not helpful for each
study. In that study, contrast was judged to be essen-
tial for the diagnosis in 21 of the 186 children (11.3%);
however, 18 of the 21 patients had a known history of
neoplasm (15, unpubl. data). The authors concluded
that gadolinium should definitely be part of the imaging
protocol in patients with known neoplasm (brain and
spine) and in patients with known/suspected vascular
malformations as well as in those with a concern for
infection (15). If these guidelines are followed, the
potential call-back rate for contrast-enhanced imaging
would be quite low (13–15, unpubl. data).
The value of contrast is undisputed in situations like
staging of and/or follow-up of malignancies, known or
suspected infections, and inflammatory conditions in
neuroimaging. The same account in other areas of radi-
ology, eg, certain studies of congenital heart disease,
bone and soft-tissue tumors, and abdominal conditions
as suspected neuro- and nephroblastoma (Table 1).
The indiscriminate use of gadolinium adds unneces-
sary costs and time to the MR examination. Additional
postcontrast sequences prolong the examination by
approximately one-third. In children who need seda-
tion, this results in extra time under conscious seda-
tion or general anesthesia, and although the associated
risks are small, complications such as oxygen
Table 1
Recommendations for the Most Relevant Use of Gadolinium-Based Contrast Media (GBCM) in Pregnant or
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desaturation, airway management issues, and overse-
dation have been reported (55). This has to be weighed
against the risks associated with repeated anesthesia
for postcontrast imaging in those cases when the pri-
mary exam is performed without contrast but reveals a
lesion that needs characterization with gadolinium.
The use of MRI protocols that include routine
administration of contrast media can be perceived as a
‘‘defensive’’ practice of medicine. However, the pressure
from referring clinicians and even radiologists to obtain
as much information as possible from the MRI study in
children in anesthesia cannot be neglected; therefore,
these patients are more likely to receive contrast. Also,
MRI of small children constitutes a relatively small vol-
ume of MRI and it can be difficult to gain some reliable
experience of the value of contrast media administra-
tion in smaller MRI centers which, therefore, may pro-
ceed with protocols routinely including gadolinium.
As the administration of contrast media in children,
unlike that in adults, is associated with issues of pro-
longed sedation/anesthesia, it is therefore desirable
that centers with large pediatric clientele evaluate and
give guidelines for the use of contrast media in spe-
cific indications.
Nephrogenic Systemic Fibrosis (NSF) in Pregnant
Women and in Children
NSF, the clinical aspects of which have recently been
presented in a special issue on NSF in this journal
(56), is linked to the injection of gadolinium-based
contrast media in patients with impaired renal func-
tion. Its frequency is very low, varying from negligible
up to 2%–5% in selected high-risk clinical situations
(57–62). The risk factors include patients with a glo-
merular filtration rate (GFR) below 30 mL/min/
1.73 m2 body surface (chronic kidney disease [CKD]
stages 4–5), high-dose gadolinium-based contrast me-
dium administration, inflammatory conditions, post-
operative state, and hyperphosphatemia. Most patients
with NSF have a very low renal function, many being in
endstage renal disease and on dialysis. Some reports
indicate the risk of NSF in the group of renal function
between 59–30 ml/min/1.73 m2 body surface (CKD
stage 3). Approximately 400–500 NSF patients have
been reported at the time when 150 million gadolin-
ium injections were administered (63). The most com-
monly reported gadolinium agent associated with NSF,
in relation to number of administered doses, is gadodia-
mide (Omniscan, GE Healthcare, St. Giles, UK) followed
by gadoversetamide (Optimark, Covidien/Mallinckrodt,
St. Louis, MO), and gadopentetate dimeglumine (Mag-
nevist, Schering Pharma, Berlin, Germany) (64).
European and FDA guidelines for gadolinium use in
risk groups differ.
In November of 2009 the European Medicines
Agency (EMEA) released that they has adopted new
recommendations to minimize risk of NSF with gado-
linium-containing contrast agents in patients at risk
of developing the condition. The Agency’s Committee
for Medicinal Products for Human Use (CHMP) classi-
fied the gadolinium-based agents into three groups:
highest risk of NSF, intermediate risk of NSF, and
lowest risk of NSF. This classification is also adopted
by the Contrast Media Safety Committee of the Euro-
pean Society of Urogenital Radiology (39). EMEA has
issued contraindications for high-risk gadolinium-
containing agents in patients with severe kidney dis-
ease (with GFR <30 mL/min), patients with scheduled
or recently received liver transplant, but more impor-
tant in this context, in newborn babies up to 4 weeks.
The agents classified as ‘‘highest risk of NSF’’ are gado-
diamide (Omniscan), gadopentetate dimeglumine (Mag-
nevist), and gadoversetamide (Optimark). The other
agents can be used in these patients with caution and
the smallest possible dose. In addition, if a ‘‘high-risk
agent’’ is used in breastfeeding mothers it is stated ‘‘as
a precaution, breastfeeding should be discontinued for
at least 24 hours after the patient has received a ‘high-
risk agent’.’’ There is no full scientific evidence for
grouping the agents in different risk classes and it is
based on ‘‘the best of knowledge’’ taking both experi-
mental and clinical studies into account.
FDA guidelines are general and there are announced
black-box warnings for the use of all gadolinium
agents in patients with acute and chronic severe renal
insufficiency GFR <30 mL/min/1.73 m2) or acute re-
nal insufficiency of any severity due to hepatorenal
syndrome or in the perioperative liver transplantation
period (65,66). The FDA has issued statements that
suggest a careful use of gadolinium-based contrast
agents, particularly in infants due to the physiological
immature kidney in the first weeks of life.
To our knowledge, no cases are linked to pregnant
women or have been reported in children under the
age of 8 years (67–69). To date, a total of nine cases of
NSF in children age 8–19 years have been reported,
all with serious renal endstage disease (67,68,70).
LIMITATIONS
The review does not cover organ-specific gadolinium-
based contrast media.
CONCLUSIONS
As the knowledge—both documentation and reports—
of possible adverse effects of gadolinium-based con-
trast media on the fetus is very limited, it is still wise
to limit the administration of gadolinium-based con-
trast media to pregnant women in situations when
the added information is considered necessary/essen-
tial for further treatment.
There is no real reason to discontinue breastfeeding
for 24 hours after the administration of gadolinium-
based contrast media.
With the increased awareness of the negative effects
of ionizing radiation to infants and children, there is
an advantage of using MRI over CT in children. How-
ever, the indiscriminate use of contrast media in small
children should be avoided for reasons of both pro-
longed scan time and need for longer sedation, as well
as limited experience in the safety of gadolinium-
based agents, especially in infants.
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NSF is not a specific problem in pregnant women
and small children but the same restrictions with
respect to reduced kidney function should apply to
pregnant women and children as to other patients
undergoing MRI. The physiologically immature kidney
in early life should receive special attention.
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